TTrialPathMatch Me to Trials
← Back to trials
RecruitingInsulin ResistanceNAFLD

Reversal of Lipid-Induced Insulin Resistance

Eligible age

18–90 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have a family history of type 2 diabetes. Hepatic mitochondrial oxidation will be assesses using a 3 hour triple tracer study (D7 glucose, 3-13C lactate and 13C4 beta-hydroxybutyrate).

Sponsor: Yale University

You may qualify if…

  • ✓ Healthy, sedentary, non-smoking and not taking any medications other than birth control pills.
  • ✓ Hematocrit \>35%
  • ✓ Subjects will have no systemic or organ disease including diabetes.
  • ✓ Subjects will have no history eating disorders.
  • ✓ Women must be using a form of birth control (sexual abstinence, birth control pills, Norplant, IUD or condoms) and will be studied between day 0 and 7 of their menstrual cycle.
  • ✓ Those who are taking birth control pills or have had a hysterectomy may be studied at any time.
  • ✓ Physical activity will be assessed using a standard questionnaire with an activity index cut off at 2.3.

You may not qualify if…

  • ✕ Any subject, who does not fit the inclusion criteria. Including history of eating disorders, any systemic and organ disease including diabetes.
  • ✕ Lactose intolerance Any blood count, clotting abnormalities HYpertriglyceridemeia (TG over 100 mg/dL)
  • ✕ Hematocrit \<35%.
  • ✕ Women of childbearing potential, who are not using contraception (as mentioned above) or who are not abstinent.
  • ✕ Subjects who have a regular exercise regimen will not be enrolled.
  • ✕ Metal implants and/or body piercing, which cannot be removed before the MR studies.

Where it's recruiting

Connecticut

New Haven

Source: ClinicalTrials.gov · NCT02193295 · last updated 2026-06-22

Reversal of Lipid-Induced Insulin Resistance · TrialPath